Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_3
1
33%
Ph phase_1
1
33%
Ph phase_4
1
33%

Phase Distribution

1

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)

Detailed Status

Not yet recruiting1
Withdrawn1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (33.3%)
Phase 31 (33.3%)
Phase 41 (33.3%)

Trials by Status

not_yet_recruiting133%
withdrawn133%
completed133%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruitingphase_3

Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase Producing Enterobacterales Undergoing Liver Transplantation

NCT07759453
withdrawnphase_4

Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections

NCT04785924
completedphase_1

Imipenem-Relebactam Pharmacokinetics in Augmented Renal Clearance

NCT04147221

Clinical Trials (3)

Showing 3 of 3 trials
NCT07759453Phase 3

Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase Producing Enterobacterales Undergoing Liver Transplantation

Not Yet Recruiting
NCT04785924Phase 4

Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections

Withdrawn
NCT04147221Phase 1

Imipenem-Relebactam Pharmacokinetics in Augmented Renal Clearance

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3